<code id='DAE14DC230'></code><style id='DAE14DC230'></style>
    • <acronym id='DAE14DC230'></acronym>
      <center id='DAE14DC230'><center id='DAE14DC230'><tfoot id='DAE14DC230'></tfoot></center><abbr id='DAE14DC230'><dir id='DAE14DC230'><tfoot id='DAE14DC230'></tfoot><noframes id='DAE14DC230'>

    • <optgroup id='DAE14DC230'><strike id='DAE14DC230'><sup id='DAE14DC230'></sup></strike><code id='DAE14DC230'></code></optgroup>
        1. <b id='DAE14DC230'><label id='DAE14DC230'><select id='DAE14DC230'><dt id='DAE14DC230'><span id='DAE14DC230'></span></dt></select></label></b><u id='DAE14DC230'></u>
          <i id='DAE14DC230'><strike id='DAE14DC230'><tt id='DAE14DC230'><pre id='DAE14DC230'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:hotspot    Page View:38893
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In